HAE
Haemonetics Corporation NYSE Listed May 10, 1991$54.39
Mkt Cap $2.5B
52w Low $47.32
17.7% of range
52w High $87.32
50d MA $59.61
200d MA $63.26
P/E (TTM)
17.9x
EV/EBITDA
11.5x
P/B
3.6x
Debt/Equity
1.5x
ROE
19.2%
P/FCF
22.3x
RSI (14)
—
ATR (14)
—
Beta
0.36
50d MA
$59.61
200d MA
$63.26
Avg Volume
823.0K
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
125 Summer Street · Boston, MA 02110 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 52.67 | +8.4% | +3.2% | — | — | — | — | — |
| Feb 5, 2026 | AMC | 1.27 | 1.31 | +3.1% | 65.02 | +0.3% | -8.7% | -2.8% | +3.1% | -3.3% | +0.2% | — |
| Nov 6, 2025 | AMC | 1.12 | 1.27 | +13.4% | 67.11 | +0.3% | +1.9% | +3.1% | +1.8% | +1.9% | +1.1% | — |
| Aug 7, 2025 | AMC | 1.01 | 1.10 | +8.9% | 55.63 | -0.7% | -2.9% | -2.8% | -0.5% | +3.2% | -2.9% | — |
| May 8, 2025 | AMC | 1.22 | 1.24 | +1.6% | 68.01 | -0.4% | +0.3% | +3.0% | -1.6% | -0.7% | +1.1% | — |
| Feb 6, 2025 | AMC | 1.18 | 1.19 | +0.8% | 62.99 | -1.7% | -5.8% | +2.2% | +1.5% | -0.4% | +1.6% | — |
| Nov 7, 2024 | AMC | 1.09 | 1.12 | +2.8% | 86.53 | +0.9% | +1.0% | +4.6% | +2.2% | -1.7% | -1.1% | — |
| Aug 8, 2024 | AMC | 1.03 | 1.02 | -1.0% | 76.43 | +1.2% | +0.8% | -3.1% | -0.5% | -1.5% | +1.1% | — |
| May 9, 2024 | AMC | 0.88 | 0.90 | +2.3% | 92.60 | +1.8% | +3.5% | +0.4% | +1.2% | -0.9% | -1.8% | — |
| Feb 8, 2024 | AMC | 0.97 | 1.04 | +7.2% | 78.11 | -0.3% | -5.0% | +0.8% | -4.1% | -0.6% | +0.9% | — |
| Nov 2, 2023 | AMC | 0.94 | 0.99 | +5.3% | 85.46 | +2.7% | +3.5% | +0.0% | +0.1% | -2.7% | -0.7% | — |
| Aug 8, 2023 | AMC | 0.73 | 1.05 | +43.8% | 89.94 | +1.4% | +0.5% | +0.6% | +0.4% | +1.6% | +0.0% | — |
| May 11, 2023 | AMC | 0.68 | 0.77 | +13.2% | 85.84 | +1.4% | +4.2% | -0.3% | +0.1% | -4.1% | -2.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 13 | Mizuho | Maintains | Outperform → Outperform | — | $57.32 | $57.28 | -0.1% | +3.4% | +2.0% | +2.4% | -3.0% | +2.5% |
| Mar 11 | Citigroup | Maintains | Neutral → Neutral | — | $62.85 | $62.37 | -0.8% | -3.5% | -1.9% | +0.7% | -0.4% | +0.6% |
| Feb 6 | BTIG | Maintains | Buy → Buy | — | $65.02 | $65.19 | +0.3% | -8.7% | -2.8% | +3.1% | -3.3% | +0.2% |
| Feb 6 | Citigroup | Maintains | Neutral → Neutral | — | $65.02 | $65.19 | +0.3% | -8.7% | -2.8% | +3.1% | -3.3% | +0.2% |
| Feb 6 | Barrington Research | Maintains | Outperform → Outperform | — | $65.02 | $65.19 | +0.3% | -8.7% | -2.8% | +3.1% | -3.3% | +0.2% |
| Feb 6 | Mizuho | Maintains | Outperform → Outperform | — | $65.02 | $65.19 | +0.3% | -8.7% | -2.8% | +3.1% | -3.3% | +0.2% |
| Feb 2 | Barrington Research | Maintains | Outperform → Outperform | — | $66.66 | $66.73 | +0.1% | -1.3% | -1.4% | +1.7% | -1.4% | -8.7% |
| Jan 12 | Barrington Research | Maintains | Outperform → Outperform | — | $82.03 | $82.34 | +0.4% | +1.1% | -4.9% | -3.9% | -2.3% | -2.5% |
| Jan 9 | BTIG | Maintains | Buy → Buy | — | $84.04 | $84.13 | +0.1% | -2.4% | +1.1% | -4.9% | -3.9% | -2.3% |
| Dec 17 | Mizuho | Maintains | Outperform → Outperform | — | $81.11 | $80.80 | -0.4% | -1.4% | -0.1% | +0.4% | +0.2% | +0.0% |
| Dec 15 | Baird | Maintains | Outperform → Outperform | — | $83.49 | $82.32 | -1.4% | -3.7% | +0.9% | -1.4% | -0.1% | +0.4% |
| Dec 15 | Needham | Downgrade | Buy → Hold | — | $83.49 | $82.32 | -1.4% | -3.7% | +0.9% | -1.4% | -0.1% | +0.4% |
| Dec 12 | JP Morgan | Maintains | Neutral → Neutral | — | $84.45 | $83.84 | -0.7% | -1.1% | -3.7% | +0.9% | -1.4% | -0.1% |
| Dec 11 | Citigroup | Downgrade | Buy → Neutral | — | $87.16 | $85.86 | -1.5% | -3.1% | -1.1% | -3.7% | +0.9% | -1.4% |
| Nov 21 | BTIG | Maintains | Buy → Buy | — | $75.12 | $75.73 | +0.8% | +4.9% | +1.1% | +1.2% | +0.1% | +0.7% |
| Nov 7 | Barrington Research | Maintains | Outperform → Outperform | — | $67.11 | $67.31 | +0.3% | +1.9% | +3.1% | +1.8% | +1.9% | +1.1% |
| Nov 7 | Needham | Maintains | Buy → Buy | — | $67.11 | $67.31 | +0.3% | +1.9% | +3.1% | +1.8% | +1.9% | +1.1% |
| Nov 6 | BTIG | Maintains | Buy → Buy | — | $50.72 | $56.88 | +12.1% | +32.3% | +1.9% | +3.1% | +1.8% | +1.9% |
| Oct 21 | Barrington Research | Maintains | Outperform → Outperform | — | $50.71 | $50.58 | -0.3% | +0.9% | +0.3% | +0.0% | -0.2% | -0.1% |
| Oct 7 | Citigroup | Maintains | Buy → Buy | — | $49.55 | $49.46 | -0.2% | -0.6% | +3.5% | -1.6% | -2.6% | +2.8% |
| Sep 23 | Barrington Research | Maintains | Outperform → Outperform | — | $51.18 | $51.11 | -0.1% | -1.0% | -0.1% | -5.8% | +1.0% | -0.1% |
| Aug 11 | Raymond James | Downgrade | Strong Buy → Outperform | — | $53.99 | $53.80 | -0.4% | -2.8% | -0.5% | +3.2% | -2.9% | +2.7% |
| Aug 8 | Mizuho | Maintains | Outperform → Outperform | — | $55.63 | $55.25 | -0.7% | -2.9% | -2.8% | -0.5% | +3.2% | -2.9% |
| Aug 8 | JP Morgan | Downgrade | Overweight → Neutral | — | $55.63 | $55.25 | -0.7% | -2.9% | -2.8% | -0.5% | +3.2% | -2.9% |
| Aug 8 | Barrington Research | Maintains | Outperform → Outperform | — | $55.63 | $55.25 | -0.7% | -2.9% | -2.8% | -0.5% | +3.2% | -2.9% |
| Aug 7 | Needham | Maintains | Buy → Buy | — | $75.77 | $72.08 | -4.9% | -26.6% | -2.9% | -2.8% | -0.5% | +3.2% |
| Jul 11 | Barrington Research | Maintains | Outperform → Outperform | — | $78.17 | $77.66 | -0.7% | -3.4% | +1.5% | -2.7% | -0.3% | -1.3% |
| Jul 9 | Citigroup | Upgrade | Neutral → Buy | — | $75.97 | $77.86 | +2.5% | +2.0% | +0.8% | -3.4% | +1.5% | -2.7% |
| May 20 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $69.36 | $68.86 | -0.7% | -0.6% | -2.9% | -1.1% | -0.2% | +2.9% |
| May 9 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $68.01 | $67.75 | -0.4% | +0.3% | +3.0% | -1.6% | -0.7% | +1.1% |
| May 8 | Needham | Maintains | Buy → Buy | — | $64.25 | $66.82 | +4.0% | +5.9% | +0.3% | +3.0% | -1.6% | -0.7% |
| Feb 7 | Barrington Research | Maintains | Outperform → Outperform | — | $62.99 | $61.93 | -1.7% | -5.8% | +2.2% | +1.5% | -0.4% | +1.6% |
| Feb 7 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $62.99 | $61.93 | -1.7% | -5.8% | +2.2% | +1.5% | -0.4% | +1.6% |
| Feb 7 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $62.99 | $61.93 | -1.7% | -5.8% | +2.2% | +1.5% | -0.4% | +1.6% |
| Feb 7 | Needham | Maintains | Buy → Buy | — | $62.99 | $61.93 | -1.7% | -5.8% | +2.2% | +1.5% | -0.4% | +1.6% |
| Dec 4 | Barrington Research | Maintains | Outperform → Outperform | — | $85.26 | $85.58 | +0.4% | -2.1% | -3.4% | +0.6% | +2.2% | +1.1% |
| Dec 3 | Needham | Maintains | Buy → Buy | — | $87.48 | $88.03 | +0.6% | -2.5% | -2.1% | -3.4% | +0.6% | +2.2% |
| Nov 15 | Needham | Maintains | Buy → Buy | — | $90.75 | $91.37 | +0.7% | -1.7% | -1.2% | -3.8% | +0.1% | +0.6% |
| Nov 8 | Raymond James | Upgrade | Outperform → Strong Buy | — | $86.53 | $87.27 | +0.9% | +1.0% | +4.6% | +2.2% | -1.7% | -1.1% |
| Nov 8 | Barrington Research | Maintains | Outperform → Outperform | — | $86.53 | $87.27 | +0.9% | +1.0% | +4.6% | +2.2% | -1.7% | -1.1% |
| Sep 23 | Barrington Research | Maintains | Outperform → Outperform | — | $74.83 | $75.13 | +0.4% | +2.1% | -1.2% | -0.5% | +2.0% | +4.2% |
| Aug 22 | Citigroup | Maintains | Neutral → Neutral | — | $75.41 | $75.50 | +0.1% | +0.1% | +1.0% | +0.3% | +0.3% | -2.1% |
| Aug 13 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $74.66 | $75.00 | +0.5% | -0.5% | -1.5% | +1.1% | +1.8% | -0.7% |
| Aug 9 | Barrington Research | Maintains | Outperform → Outperform | — | $76.43 | $77.33 | +1.2% | +0.8% | -3.1% | -0.5% | -1.5% | +1.1% |
| Jun 12 | Needham | Upgrade | Hold → Buy | — | $83.41 | $86.34 | +3.5% | +3.0% | +0.1% | -1.6% | +1.1% | -0.2% |
| May 10 | Barrington Research | Maintains | Outperform → Outperform | — | $92.60 | $94.24 | +1.8% | +3.5% | +0.4% | +1.2% | -0.9% | -1.8% |
| May 10 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $92.60 | $94.24 | +1.8% | +3.5% | +0.4% | +1.2% | -0.9% | -1.8% |
| Apr 12 | Barrington Research | Maintains | Outperform → Outperform | — | $86.52 | $85.98 | -0.6% | -1.5% | -0.4% | -0.8% | +0.8% | -1.7% |
| Feb 13 | Barrington Research | Maintains | Outperform → Outperform | — | $74.77 | $73.18 | -2.1% | -4.1% | -0.6% | +0.9% | +0.7% | -1.3% |
| Nov 3 | Barrington Research | Maintains | Outperform → Outperform | — | $85.46 | $87.78 | +2.7% | +3.5% | +0.0% | +0.1% | -2.7% | -0.7% |
No insider trades available.
8-K · 2.02
!! High
Haemonetics Corporation -- 8-K 2.02: Earnings Results
Haemonetics reported Q4 and full-year fiscal 2026 results on May 7, 2026, providing investors with updated financial performance data for the medical device company's latest reporting period.
May 7
8-K · 7.01
! Medium
Haemonetics Corporation -- 8-K 7.01: Regulation FD Disclosure
Haemonetics repaid $300 million in convertible notes at maturity, eliminating this debt obligation and reducing its leverage.
Mar 3
8-K · 7.01
! Medium
Haemonetics Corporation -- 8-K 7.01: Regulation FD Disclosure
Haemonetics published its 2024-2025 Corporate Responsibility Report, providing transparency on environmental, social, and governance practices that may influence investor decisions on corporate accountability.
Feb 12
8-K
Haemonetics Corporation -- 8-K Filing
Haemonetics' Q3 results demonstrate strong organic growth and margin expansion in core operations, excluding transitional CSL Plasma sales, indicating resilient underlying business performance despite portfolio changes.
Feb 5
Data updated apr 25, 2026 12:52pm
· Source: massive.com